Literature DB >> 12770729

Ovarian hyperstimulation syndrome-model rats; the manifestation and clinical implication.

Takashi Ohba1, Takeshi Ujioka, Katsuyasu Ishikawa, Nobuyuki Tanaka, Hitoshi Okamura.   

Abstract

Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of ovulation induction with the gonadotropins. Though vascular endothelial growth factor (VEGF) has been implicated as a prime causative factor of OHSS progression, other factors must also be involved in the pathogenesis of OHSS. We have established an experimental model of OHSS in immature female rats. The ovarian weights and vascular permeability of the OHSS model rats are significantly increased by the ovarian stimulation with human chorionic gonadotropin (hCG). hCG elicits VEGF production in OHSS model rat ovaries. The addition of potent synthetic progesterone antagonist RU486, which reduces the extension of OHSS, attenuates the ovarian kinin and VEGF production dose-dependently whereas the VEGF gene expression was stable. VEGF protein detected in both the lung and the liver of the OHSS model rats is not affected at 24 h after the addition of hCG and RU486 in contrast to the ovary. Our results demonstrate that progesterone is implicated in the development of OHSS, in part, to enhance the ovarian VEGF production by post-transcriptional and organ-specific control.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12770729     DOI: 10.1016/s0303-7207(03)00061-3

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  6 in total

1.  Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: an experimental study.

Authors:  Şehmus Pala; Remzi Atilgan; Zehra Sema Ozkan; Salih Burçin Kavak; Nevin Ilhan; Nusret Akpolat; Ekrem Sapmaz
Journal:  Drug Des Devel Ther       Date:  2015-03-24       Impact factor: 4.162

2.  Can a cyclooxygenase inhibitor be an option for treatment of ovarian hyperstimulation syndrome?

Authors:  Hasan Çilgin
Journal:  Drug Des Devel Ther       Date:  2019-04-05       Impact factor: 4.162

3.  Expression of tissue factor and tissue factor pathway inhibitors during ovulation in rats: a relevance to the ovarian hyperstimulation syndrome.

Authors:  You Jee Jang; Hee Kyung Kim; Bum Chae Choi; Sang Jin Song; Jae Il Park; Sang Young Chun; Moon Kyoung Cho
Journal:  Reprod Biol Endocrinol       Date:  2021-04-01       Impact factor: 5.211

4.  Tie1 contributes to the development of ovarian hyperstimulation syndrome under the regulation of EGR1 in granulosa cells.

Authors:  Lihua Sun; Hui Tian; Songguo Xue; Hongjuan Ye; Xue Xue; Rongxiang Wang; Yu Liu; Caixia Zhang; Qiuju Chen; Shaorong Gao
Journal:  Exp Mol Med       Date:  2022-01-25       Impact factor: 12.153

5.  Transient receptor potential melastatin 2 ion channel activity in ovarian hyperstimulation syndrome physiopathology

Authors:  Cengiz Şanlı; Remzi Atılgan; Tuncay Kuloğlu; Şehmus Pala; Bilge Aydın Türk; Hasan Burak Keser; Nevin İlhan
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

6.  Co action of CFTR and AQP1 increases permeability of peritoneal epithelial cells on estrogen-induced ovarian hyper stimulation syndrome.

Authors:  Pei-Yin Jin; Yong-Chao Lu; Ling Li; Qin-Fu Han
Journal:  BMC Cell Biol       Date:  2012-08-28       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.